TY - JOUR T1 - “No test is better than a bad test”: Impact of diagnostic uncertainty in mass testing on the spread of Covid-19 JF - medRxiv DO - 10.1101/2020.04.16.20067884 SP - 2020.04.16.20067884 AU - Nicholas Gray AU - Dominic Calleja AU - Alex Wimbush AU - Enrique Miralles-Dolz AU - Ander Gray AU - Marco De-Angelis AU - Elfriede Derrer-Merk AU - Bright Uchenna Oparaji AU - Vladimir Stepanov AU - Louis Clearkin AU - Scott Ferson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/22/2020.04.16.20067884.abstract N2 - Background The cessation of lock-down measures will require an effective testing strategy. Much focus at the beginning of the UK’s Covid-19 epidemic was directed to deficiencies in the national testing capacity. The quantity of tests may seem an important focus, but other characteristics are likely more germane. False positive tests are more probable than positive tests when the overall population has a low prevalence of the disease, even with highly accurate tests.Methods We modify an SIR model to include quarantines states and test performance using publicly accessible estimates for the current situation. Three scenarios for cessation of lock-down measures are explored: (1) immediate end of lock-down measures, (2) continued lock-down with antibody testing based immunity passports, and (3) incremental relaxation of lock-down measures with active viral testing. Sensitivity, specificity, prevalence and test capacity are modified for both active viral and antibody testing to determine their population level effect on the continuing epidemic.Findings Diagnostic uncertainty can have a large effect on the epidemic dynamics of Covid-19 within the UK. The dynamics of the epidemic are more sensitive to test performance and targeting than test capacity. The quantity of tests is not a substitute for an effective strategy. Poorly targeted testing has the propensity to exacerbate the peak in infections.Interpretation The assessment that ‘no test is better than a bad test’ is broadly supported by the present analysis. Antibody testing is unlikely to be a solution to the lock-down, regardless of test quality or capacity. A well designed active viral testing strategy combined with incremental relaxation of the lock-down measures is shown to be a potential strategy to restore some social activity whilst continuing to keep infections low.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been partially funded by the EPSRC IAA exploration award with grant number EP/R511729/1, EPSRC programme grant ‘Digital twins for improved dynamic design’, EP/R006768/1, and the EPSRC and ESRC Centre for Doctoral Training in Quantification and Management of Risk and Uncertainty in Complex Systems and Environments, EP/L015927/1.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data can be made available ER -